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PATTERNS OF RESISTANCE TO ANTIRETROVIRAL THERAPY AMONG HIV+ 
PATIENTS IN CLINICAL CARE.  Akash D. Shah and Michael J. Kozal. Section of Infectious 
Diseases, Yale AIDS Program, Yale University School of Medicine, New Haven, CT.   
HIV-1 antiretroviral resistance has posed major challenges to treatment advances of the 
last decade. However, few studies have analyzed the prevalence and time trends of drug 
resistance among HIV+ patients on antiretroviral therapy followed longitudinally in clinical care.  
The purpose of this study is to determine the cumulative prevalence of HIV genotypic drug 
resistance and the dynamics of resistance development in HIV+ patients in care.  We 
hypothesized that a >5% increase in resistance would occur per 6-month period and a >15% 
increase in drug resistance would occur over 18 months. 
 This retrospective longitudinal study consisted of patients from the two largest HIV 
clinics in Connecticut who were enrolled in the Options Project Study from 2000-2003.  HIV+ 
patients were consented and enrolled in the resistance substudy.  HIV genotypic resistance testing 
was done on plasma samples available for each patient at study baseline and at ~6 month intervals 
for 18 months.  HIV viral load and resistance data were matched to behavioral and demographic 
data for each patient.  Genotypic drug resistance was defined according to the International AIDS 
Society 2004 guidelines.  The chi-square test for linear trends was used to assess resistance 
trends.   
396 HIV+ patients enrolled in the study and had archived plasma available for analysis.  
The cumulative prevalence of drug resistance increased from 32.1% to 46.3% for patients with 18 
consecutive months of data, 31.9% to 50.7% for patients with 12 consecutive months of data, and 
30.2% to 41.3% for patients with 6 consecutive months of data.      
 During the period of study for this HIV+ patient care population, the cumulative 
prevalence of HIV genotypic drug resistance rose dramatically.  The findings emphasize the need 
for addressing antiretroviral resistance in a clinical setting through physician education, reduction 
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As one of the most devastating epidemics in recent history, Acquired 
Immunodeficiency Syndrome (AIDS) has killed approximately 25 million people since 
its recognition in 1981.  An estimated 40.3 million persons were living with HIV/AIDS in 
2005.  There were 4.9 million new HIV infections and 3.1 million deaths from AIDS in 
2005 (1).  In the United States, an estimated 1.1 million persons were living with 
HIV/AIDS at the end of 2003.  Approximately 40,000 new HIV infections occur every 
year in the United States (2).  The development of antiretroviral therapy has led to a 
major reduction in mortality due to HIV disease. However, enthusiasm for these 
therapeutic advances of the past decade has been tempered in recent years by the 
development of resistance to antiretroviral therapy.   
 
Advent of Antiretroviral Therapy     
In the years immediately following the discovery of HIV, opportunistic infections 
were largely responsible for the high mortality rate among AIDS patients.  With the lack 
of therapeutic options, 85% of AIDS patients died within five years (3).  In 1987, 
zidovudine became the first drug introduced for treatment of HIV.  Zidovudine is a 
nucleoside analogue that inhibits HIV-1 reverse transcriptase, one of the proteins 
essential for viral functionality and induces chain termination of proviral DNA through 
competitive inhibition.  More nucleoside reverse transcriptase inhibitors (NRTIs) were 
introduced four years later; however, deaths from AIDS continued to increase as 
scientists recognized the quick development of resistance among patients on 
monotherapy with NRTIs (4, 5, 6).  An improved understanding of the virus itself led to 
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the discovery of protease inhibitors (PIs) in 1995.  Mature viral proteins are cleaved from 
longer polypeptides by the HIV protease enzyme, a necessary step in the viral life cycle 
that results in the production of infectious virions.  Protease inhibitors prevented the 
formation of these mature virions.  In 1997, scientists recognized the effectiveness of 
triple therapy, otherwise known as highly active antiretroviral therapy (HAART). 
HAART is generally considered an antiretroviral regimen that contains 3 drugs with at 
least one drug from two different antiretroviral classes.  Mortality of patients with AIDS 
was greatly reduced.  HAART was effective in suppressing HIV-1 viral load and 
reducing viral replication, thus minimizing the chances of developing resistance to 
therapy.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs) were also introduced.  
NNRTIs differed from NRTIs in their mechanism of action.  NNRTIs bound to a site 
distant from the active site for reverse transcriptase, leading to conformation changes in 
the active site and inhibition of DNA synthesis (7).   
 
Antiretroviral Resistance 
 The development of antiretroviral therapy for HIV ushered in a new era of 
treatment and management of the disease.  While antiretrovirals have lengthened survival 
and slowed disease progression, poor adherence due to complexities and toxicities of 
treatment regimens, insufficient regimen potency, and the biology of HIV-1 itself have 
contributed to the development of resistance.  The persistence of drug-resistant viral 
variants despite therapy has played a significant role in the direction of the HIV 
epidemic.  Resistance to zidovudine was first described in 1989 by Larder B et al. (4) 
with mutations in the HIV-1 reverse transcriptase gene (8).  Of individuals on ddI 
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monotherapy, 60% developed resistance within 6 months of treatment (6).  An estimated 
30-50% of individuals on HAART were shown to have developed drug-resistant 
mutations within 2 years of therapy (9).   
Viral drug resistance is caused by the selection of viral variants with mutations 
during viral replication that persists despite antiretroviral therapy.  The high viral 
replication rate of HIV-1 (an estimated 109 virions are produced daily (10)), the poor 
fidelity of reverse transcriptase for RNA polymerase, and the lack of a viral enzyme 
proofreading capability lead to a high mutation rate in the pol gene (the gene that encodes 
the reverse transcriptase and protease enzymes), estimated at ~ one mutation per 
replication. These viral dynamics ensure that viral replication that occurs during therapy 
will result in the development of drug resistance and eventual virological rebound.  
Although some viral mutations may have a negative impact on the replication capability 
of the virus (11), HIV has demonstrated the ability to function despite multiple resistance 
mutations. Further, the virus will continue to develop mutations in the face of drug 
pressure. These additional mutations, termed compensatory mutations, help increase the 
virus’s replication capability in the face of antiretroviral therapy (11).        
 
Viral Latency  
Although the dominant viral population in an individual at any given time may 
show no drug resistance, the high replication and mutation rates of HIV-1 point to the 
likelihood that subpopulations of the virus exist that contain perhaps all possible 
mutations (12).  It has been shown that viral populations in the CNS and semen exist 
independently of populations found in blood cells and these body compartments can 
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harbor viral variants with resistance (7, 13).  An estimated 107-108 infected cells can exist 
in lymphoid tissues in a steady state (14).  Given the short half-life of infected cells, the 
virus must have a high replication rate, with resulting mutations contributing to a 
diversity of viral quasispecies. Because HAART often does not inhibit viral replication 
completely, latent infections in resting memory CD4+ T cells, macrophages, and 
monocytes, which can survive for long periods of time, contain many quasispecies that 
can reemerge once the suppressive pressure of HAART is removed (10). 
 
Risk Factors for Antiretroviral Resistance 
 Drug resistance in HIV can emerge 1) with a failure to suppress HIV-1 RNA to 
nondetectable levels 2)  with subtherapeutic plasma and intracellular drug levels due to a 
lack of adherence from regimen complexities/toxicities, borderline pharmacokinetics, and 
drug-drug or drug-food interactions and 3) with non-potent regimens e.g. sequential 
monotherapy; dual therapy or single class therapy (12).   Resistant strains do not 
necessarily lead to virological failure (unless a patient is primarily infected with resistant 
strains – this leads to failure if not recognized), but instead develop in the setting of 
treatment failure characterized by quantities of drug both effective enough to exert a 
positive selective pressure but not sufficient enough to inhibit viral replication completely 
(15).   In a population-based study of individuals followed for 30 months after initiation 
of HAART therapy, high baseline plasma viral loads, history of injection drug use, and 
<95% adherence were associated with drug-resistant mutations (15). The association with 
high baseline plasma viral loads likely reflects incomplete viral suppression as well as the 
 5
greater presence of minority HIV-1 quasispecies, and a larger pool of latently infected 
cells (and acutely infected cells) in these individuals.        
 Of note, the association between drug resistance and adherence is thought to 
follow a bell-shaped curve.  The presence of antiretroviral drugs creates a selective 
pressure for drug-resistant mutations to develop.  At the same time, high levels of 
adherence can suppress viral replication and inhibit development of drug resistance.  In a 
study of 87 patients on protease inhibitor therapy, the peak rate of drug-resistant 
mutations was 2.08 over 12 months in patients that had 100% adherence but still had 
viremia – active viral replication in the face of non-fully suppressive drug exposure.    
However, 48% of these patients had nondetectable VL (VL<50), reducing this rate to 
1.08 mutations.  When considering both viremic and nonviremic patients, the peak rate of 
drug-resistant mutations occurred at 87% adherence (16).  This suggests that a high level 
of adherence is associated with decreased risk of resistance due to the percentage of 
highly-adherent patients with nonviremia.  When the assumed viral suppression in 100%-
adherent patients was 95%, the peak rate of protease-inhibitor resistance was calculated 
to occur at 45% adherence.  Thus, to clarify the association between drug resistance and 
adherence, drug resistance is more common in patients with simultaneously high 
adherence levels and incomplete viral suppression.  Other studies have determined that 
this bell-shaped curve may not be accurate for NNRTI-resistance. Recent data from 
Bangsberg and colleagues suggest the drug resistance to NNRTIs can occur with as little 




Prevalence of Antiretroviral Resistance  
In the era of HAART therapy, the development of drug resistance has been aided 
by low adherence, subtherapeutic drug levels, and transmission of resistant viral strains as 
patients live longer and healthier lives and continue to engage in HIV transmission risk 
behaviors which include unprotected sex and the sharing of injection drug needles/works.  
Resistance occurs not only in chronically infected patients on treatment, but also in newly 
infected people without treatment due to the exposure to drug resistant strains during the 
transmission event. 
In a study of newly-infected patients between 1989 and 1998 with a history of 
HIV seroconversion in the preceding twelve months and less than seven days of total 
antiretroviral therapy, resistance was measured by phenotypic drug susceptibility 
reduction.  Two percent of patients had a greater than 10-fold reduction in susceptibility 
to one or more drugs and resistance was confirmed by genotypic sequence testing for 
drug-resistant mutations.  Twenty-six percent of patients had a 2.5 to 10-fold reduction in 
susceptibility (18).  A study of drug-naïve patients from 10 cities between 1997 and 2001 
showed 8.3% of patients with RTI- or PI-resistant mutations.  The prevalence of 
resistance differed by sexual orientation (11.6% among men who had sex with men vs. 
4.7% among heterosexual men), race (13.0% among whites vs. 5.4% among African-
Americans and 7.9% among Hispanics), and status of sexual partners (15.2% among 
patients whose partners were on antiretroviral therapy (19).  Figure 1, adapted from 
Bennett D et al. (20) shows the most recent data from the CDC presented at CROI in 
2005 on drug resistance in newly diagnosed treatment-naïve patients by demographics 
and drug class.   
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CDC data on prevalence of drug resistance in 787 newly diagnosed








Figure 1. Prevalence of drug resistance in newly diagnosed ART-naïve 
subjects by demographic and drug class 
 
In chronically HIV-infected, treatment-naïve patients, a 10.8% prevalence of 
resistance was found in one cohort.  There was a 40% increase per year in prevalence of 
drug-resistant mutations in cohorts analyzed from 1999 to 2001 (21).   
From a representative sample of 1800 HIV-infected patients receiving care in 
1998, it was estimated that 76% of HIV-infected adults with viremia (VL>500 copies 
HIV RNA/ml plasma) at the time were resistant to at least one antiretroviral drug.  Higher 
levels of resistance were independently associated with current HAART therapy, lowest 
reported CD4 count, and high viral load.  Of note, the reported prevalence was among 
patients with detectable viral load.  If all patients without a detectable viral load were 
assumed to harbor non-resistant virus, the prevalence was still 48%.  This analysis 
provided an important description of the high prevalence of resistance among patients in 
the early years of HAART (22), when many patients were the survivors of serial 




Because of the possibility of archived mutations in latently infected T-cells, cross-
sectional genotyping, which does not take into account the genotypic history of an 
individual, can underestimate the number of drug-resistant mutations present.  A single 
genotypic analysis analyzes the dominant viral strain circulating in a patient’s plasma.  
However, true burden of resistance would be underestimated if a patient harbored a 
subpopulation of drug-resistant virus that was actively being suppressed due to sufficient 
therapeutic suppression with long-term therapy.  In a retrospective study of HIV patients 
in British Columbia who had undergone at least 3 genotyping tests between 1996 and 
2004, a historical genotype profile was created for each patient and compared to the 
results of the most recent genotype test as well as the most recent genotype on therapy for 
each patient.  Prevalence of drug-resistant mutations was higher when the genotypic 
history was taken into account than only in the most recent genotypic test.  For example, 
14% of subjects had the PI L90M mutation in their genotypic history vs. 8% in their most 
recent genotype.  For NRTIs, 58% of subjects had the M184V mutation in their genotypic 
history vs.  24% of subjects with this mutation in their most recent genotypic test.  For all 
drug-resistant mutations combined, a 12% historical prevalence of resistance was 
underestimated at 5% using only the most recent genotypic test.  Thus, historical 
genotypic testing, which accounts for more possible drug-resistant mutations in an 
individual, is more likely to account for the prevalence of resistance in a population.  
Historical genotyping, which takes into account the presence of archived mutations, is 
important to note in any patient as subpopulations of drug-resistant virus can reemerge 
quickly with resumption of or changes to therapy (23).     
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Viral Fitness  
 Drug-resistant mutations can impair viral fitness by lowering the enzymatic 
efficiency of target enzymes resulting in an inefficient process of replication.  CD4 
counts have been shown to remain stable despite the development of resistance, and 
continue to decline once the selective pressure of therapy is removed (24).  While this 
may suggest the possibility of residual drug function despite resistance, the lower 
virulence of the resistant virus may also contribute to a stable CD4 count (18). 
 
Time Trends in Prevalence of Antiretroviral Resistance  
Prevalence of HIV drug resistance in the newly infected population has been 
rising over time.  In a study of newly-infected patients from ten North American cities, 
the prevalence of drug-resistance detected by 10-fold reductions in drug susceptibility 
3.4% in 1995 to 12.4% in 2000, and as tested by sequence analysis increased from 8.0% 
in 1995 to 22.7% in 2000.  The frequency of multi-drug resistance increased from 1.1% 
to 6.2% by phenotypic susceptibility testing and 3.8% to 10.2% by sequence analysis 
during the same period.   While the results vary based on the method of testing for 
resistance, the results clearly suggest increasing transmission of drug-resistant virus over 
time (25). 
 Resistance to different classes of drugs has been shown to increase at different 
rates.  A case series study of 225 patients with recent HIV-1 infection between 1996 and 
2001 at a hospital in San Francisco found an increase of resistance to NNRTIs from 0% 
in 1996 to 13.2% in 2001.  This likely reflects the increasing prevalence of NNRTIs 
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during the latter half of this period.  Also, NNRTI-resistance can develop more easily 
from one-step high-level mutations which greatly reduce susceptibility.  Resistance to PIs 
remained stable during this period (26).   
 
Clinical Implications of Resistance 
Development of antiretroviral resistance has been associated with decreased treatment 
options for patients (18, 27).   It has also been associated with clinical progression of 
disease and mortality.  In a study of 1388 ART-naïve patients in Canada who initiated 
HAART therapy from 1996-2000, all-cause mortality was followed.  Emergence of ART 
resistance, a higher baseline VL, and decreased adherence were among the factors 
associated with an increased risk of death.  Resistance to any drug represented a hazard 
ratio of 1.8.  Resistance to non-3TC NRTIs represented a hazard ratio of 2.93 (28). 
In a retrospective analysis of patients from the AIDS Clinical Trials Group protocol 
with zidovudine-resistance, associations between zidovudine resistance and HIV-1 isolate 
synctium-inducing phenotypes, CD4 count, HIV-1 disease stage, and treatment were 
analyzed.  The synctium-inducing phenotype, signifying a multinucleated cell mass, 
predicts clinical and immunologic deterioration.  High-level zidovudine resistance in this 
study predicted accelerated disease progression and death.  Moderate resistance was not 
similarly associated with these outcomes.  Importantly, other predictors of progression, 
including synctium-inducing phenotype, baseline CD4 count and diagnosis of AIDS were 
controlled for in this study.  While synctium-inducing phenotype predicted mortality, it 
was not associated with high-level zidovudine resistance (29). 
 11
Studies have also found associations between antiretroviral resistance and CD4 count 
and viral burden (5, 6).  In a retrospective study of patients switched from zidovudine and 
didanosine with subsequent development of a didanosine-resistant mutation, significant 
decreases in CD4 count and increase in HIV RNA levels were seen (6).  In a trial 
measuring phenotypic susceptibility in NRTI-experienced patients, reduced phenotypic 
susceptibility at baseline predicted virological failure (30).     
 
Resistance Testing 
Due to the negative clinical impact of resistance development, testing for resistance in 
clinical settings has been recommended in patients experiencing virological failure on a 
stable antiretroviral regimen as well as treatment-naïve patients acutely infected with 
HIV. With the high prevalence of resistance in newly-infected HIV+ patients, 
susceptibility testing is to be strongly considered (19, 20). Testing is also likely useful in 
treatment-naïve patients chronically infected with HIV.  In chronically-infected HIV+ 
patients, testing is generally considered helpful in populations with a high prevalence of 
resistance.  Genotype testing is in fact considered cost effective in most clinical scenarios 
(acute, chronic, pregnancy, etc.) (12).   
 
It is clear that HIV drug resistance is a major problem both in treatment-naïve and 
treatment-experienced HIV-1 infected populations. A better understanding of the 
dynamics of resistance development and the overall burden of resistance among patients 
in clinical care is needed to better design strategies to prevent the development of and 
treat drug-resistant strains.  
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STATEMENT OF PURPOSE  
 In this setting of increasing resistance and continued risk behaviors, development 
and transmission of drug-resistant virus have become important points of focus in current 
research on HIV.  Recent clinical trials have documented the prevalence of resistance 
over time in newly and chronically infected patients.  While these studies have 
documented a rising prevalence of antiretroviral resistance in large HIV patient 
populations, there have been no clinic-level studies on the change in prevalence of 
antiretroviral resistance in HIV+ patients.  Little data exists on the prevalence and time 
trends of HIV resistance among HIV+ patients for whom antiretroviral agents are 
prescribed and who are being followed longitudinally in clinical care.  Previous studies 
have shown that this population is a likely source of continuing transmission of drug-
resistant virus (31, 32).  A better understanding of the dynamics of resistance over time, 
the development of new mutations, and associations between resistance and patient 




Previous literature has documented both the transmission of drug-resistant virus 
among all patient groups and continued risk behaviors in clinic populations.  Given the 
presence of archived mutations in latently infected T-cells, the hypothesis in this study is 
that the cumulative prevalence of ART resistance, based on historical genotype results, in 
the clinic population to any ART class (reverse transcriptase inhibitors (RTI), non-
nucleoside RTI (NNRTI), protease inhibitors (PI)) will increase at a rate of >5% per 6-
 13
month interval.  The cumulative rate of increase during the 18-month period of data in 
this study will exceed 15%.  The importance of this hypothesis is that an increasing and 
significant number of individuals within the cohort will develop the potential for 




 This study is an extension of the Options Project.  The Options Project is an 
NIMH-funded study from which biologic data has been collected towards the 
investigation of antiretroviral resistance, adherence, and transmission risk behavior.  The 
central focus of the Options Project is to analyze the effect of a physician-delivered 
intervention aimed to reduce HIV transmission risk behaviors in the setting of clinical 
care of HIV patients (33).  Data was collected at baseline and follow-up visits on 
transmission risk behavior, length of time on therapy, gender, age, educational level, 
income level, support resources, welfare use, sexual orientation, duration of HIV, race, 
CD4, viral load (VL), and HIV risk factor.  The present study is part of a supplemental 
substudy of the Options Project specifically focused on viral resistance development.   
 
Delineation of Work 
This study represents an analysis of demographic and resistance data obtained 
from patients in the Options Project resistance substudy. Patient recruitment for the 
resistance substudy, sample collection, and laboratory resistance testing were completed 
by Dr. Michael Kozal’s team.  Data organization was completed by Akash Shah with the 
assistance of Michael Kozal, MD, Jennifer Chiarella, and Rivet Amico, PhD.  Data 
analysis and results were completed by Akash Shah with the assistance of Michael Kozal, 
MD for data interpretation.  Statistical analysis was completed by Akash Shah with the 





 A total of 492 HIV+ patients were enrolled in the Options Project from the 
Nathan Smith Clinic (NSC) at Yale New Haven Hospital (YNHH) in New Haven, CT 
(n=247) and the Community Care Clinic at Hartford Hospital (HH) (n=245).  Subjects 
had to provide written informed consent, be at least 18 years old, be healthy enough to 
complete procedures of the study, and show no obvious signs of dementia.  The study 
was approved by the Yale University Human Investigations Committee, University of 
Connecticut IRB, and Hartford Hospital IRB.  451 patients consented to participate in the 
voluntary viral resistance substudy involving genotypic analysis between 2001 and 2003.  
Of these patients, data was obtained for 396 patients at YNHH (n=192) and HH (n=204).               
 The Nathan Smith Clinic at YNHH, serving patients in a 60-mile radius 
surrounding New Haven, CT, provides clinical care to approximately 1000 HIV+ 
patients.  During the data collection period of the present study, 15 attending physicians, 
fellows, and physician assistants from the Infectious Diseases section at Yale School of 
Medicine provided care at the clinic.  Within the clinic population, 35% of patients at the 
clinic are women.  45% of the patients are Caucasian, 40% are African-American, and 
15% are Hispanic.  A history of intravenous drug use (IDU) is the most common risk 
factor for acquisition of HIV among these patients at 45% of patients, followed by 30% 
with male same sex contact (MSM) and 25% with heterosexual contact.  
 The Community Care Clinic at HH also provides care to approximately 1000 
HIV+ patients in the Hartford, CT region.  5 physicians and 2 nurse practitioners from the 
Infectious Diseases section at HH provide clinical care.  Patient demographics are similar 
at NSC and the clinic at HH.  35% of patients at the clinic are women.  The clinic has a 
 16
greater population of Hispanics at 35% than NSC.  An additional 35% of patients are 
African-American and 30% are Caucasian.  Risk factors for HIV acquisition are similar 
to NSC, with 44% reporting a history of IDU, 24% reporting MSM, 22% reporting 
heterosexual contact, and 10% unknown.         
 
Plasma Sample Collection 
 All patients enrolled in the Options Project had plasma samples routinely drawn 
for measurement of VL and CD4 approximately every 3 months as part of the standard of 
clinical care.  Approval was obtained to utilize the remaining specimens for resistance 
testing.  Thus, no additional plasma specimens were required with enrollment in the 
resistance substudy.  Unused specimens were saved for one year, and approximately 1-4 
ml of plasma was still available after VL testing for each sample.  Specimens from NSC 
were transported to the testing laboratory weekly.  Specimens from HH were shipped 
when a sufficient sample size had accumulated in order to save costs.   
Genotype data was recorded from plasma samples available for each patient at the 
first visit at the initiation of the study (baseline) and at approximate 6-month intervals for 
18 months.  HIV genotyping was not performed in samples with a nondetectable (ND) 
HIV VL as current genotyping assays require a detectable VL.  ND samples are recorded 
as such.  Samples with VL<1000 HIV RNA copies/ml are suboptimal for genotype 
testing.  However, an ultracentrifuge step added to the assaying method allowed for a 
genotype result on approximately 75% of samples with VL between 50 and 1000 HIV 
RNA/ml.  As the resistance substudy was supplemental, samples were not available for 
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every patient at every time point as genotyping was not required in the initial Options 
Project study.                      
Of note, enrollment into the study was staggered, and each patient’s baseline 
plasma sample may have been drawn on different dates during the study period.  Because 
this study is an analysis of drug resistance in continuing clinical care relative to a single 
point in patients’ clinical care, the specific baseline dates do not affect the data.   
 
Resistance Testing  
Standard methods for DNA sequencing were applied in this study to detect 
genotype resistance in the virus.  Standard ABI sequencing consists of pol gene isolation 
and sequence determination (34).  Cryopreserved (-70° C) plasma aliquot samples were 
ultracentrifuged for one hour at -4° C.  HIV-1 RNA was extracted from these samples 
using standard RNA isolation procedures.  RT-PCR was used to isolate HIV-1 nucleic 
acid and PCR using HIV PRT primers, HIV PRT Plus reaction assay conditions, and 6 
primer sets was utilized for standard ABI sequencing.  See Kozal et al. (34) for specific 
details on this sequencing methodology.     
 
Data Analysis  
 The primary aim of the study is to assess the change in prevalence of any 
genotypic resistance over time.  The study is powered to detect this outcome.  Based on 
the original sample size of 451 patients, the following assumptions are made in 
estimating the power: 1) baseline viral resistance of 24% 2) a projected increase in viral 
resistance of 10% over the 18-month period 3) drop-out rate of 5% over the 18-month 
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period.  With a Type I error of 0.05, the power to detect a 10% increase at 18 months as 
compared to baseline is 79%.  The power to detect a 15% increase is 99%.   
 Initially, the proportion of patients with 1-class, 2-class, and 3-class resistance, 
ND VL, and wild-type genotype (WT) was calculated at each time point.  To arrive at a 
complete picture of how resistance changes in this clinic population based on historical 
genotype, various methods were utilized.  Due to incomplete follow-up with all patients, 
the number of patients with plasma samples available at baseline and at each 6-month 
follow-up time point differed.  For each patient with resistance data, an identification of 
all time points with available resistance data and number of consecutive time points with 
available resistance data were recorded.  In order to analyze changes in prevalence of 
resistance over time, only those patients with at least two consecutive time points of 
genotype data available were analyzed.  Patients were divided into three groups: 1) 
patients with 4 consecutive time points with complete genotype data (18 consecutive 
months) 2) patients with at least 3 consecutive time points with complete genotype data 
(any 12 consecutive months) and 3) patients with at least 2 consecutive time points with 
complete genotype data beginning at baseline (baseline and 6 months).  In group 2, 
patients’ baselines were redefined as the first time point for which the patient had 
genotype data available.         
 Within each group of patients, the following was derived and calculated from the 
data: 1) proportion of patients with ND VL, WT genotype, back-revertants (defined as 
patients with polymorphisms at RT codon 215), 1-class resistance, 2-class resistance, 3-
class resistance, and total resistance (sum of patients with resistance to at least one drug 
class or revertant status).  For purposes of this study, patients with ND VL were assumed 
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to have not developed resistance at that time point.  The incidence of resistance was 
noted, and cumulative total resistance was calculated for each time point after baseline.  
The accumulation of additional new mutations was not analyzed once the first evidence 
of a drug-resistant or revertant mutation was documented.  The analysis was also carried 
out excluding revertants.       
  
Measurement of Resistance 
 Resistance was defined as the presence of at least 1 major drug resistance 
mutation based on guidelines from the International AIDS Society 2004 (35).  NRTI 
back-revertants from earlier mutations at sites such as 215 C/D/E/S and 69 A/N/S in the 
pol gene were included as resistant as they likely represent a past presence of complete 
resistance to NRTIs with removed drug pressure (or the ongoing selection of resistant 
strains as the virus needs to change two nucleotides at the codon 215 position to develop 
resistance and must go through an intermediate amino acid such as C/D/S before Y or F 
is selected, e.g. ACC (T)  TCC (S)  TAC (Y)).   Development of new resistance 
comprised all patients with first-time drug-resistant or revertant mutations within the 
period of the study.  Three methods were employed to assess the change in resistance 
over time within each group of patients as described below.  Method 1 is the primary 
outcome of this study and is the only method for which further statistics were computed.     
Method 1:  Prevalence of resistance was calculated at baseline as a percentage of 
patients with resistance out of a sample of all patients with known ND VL status, WT 
genotype, resistant genotype, or revertant genotype.  Due to incomplete genotype data at 
certain time points for a small number of patients (for certain samples, only a partial 
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resistance genotype assay was performed due to inadequate plasma sample – see 
Discussion for further explanation/limitations), sample size varied by time point.  In this 
method, only patients with complete genotype data for all time points comprised the 
sample.  The number of patients with first-time resistance in each subsequent time point 
was added to the cumulative incidence of resistance.  The Mantel-Haenszel chi-square 
test for linear trends was used to test for significance of changes in cumulative resistance.       
Method 2:  The incidence of resistance was calculated for each transition between 
two time points.  Patients with either 1) known development of first-time resistance, 2) 
known continuing resistance, or 3) known continuing ND VL or WT genotype for all 
time points comprised the total sample.  The sample size was higher than in Method 1, as 
patients with resistant genotypes at any earlier time point within the study would be 
automatically characterized as known continuing resistance at subsequent time points 
regardless of the completeness of the data at subsequent time points.  Patients not 
meeting any of the three criteria at any single time point were excluded from the sample 
at all time points.  For example, a patient with ND VL at baseline, WT genotype at 6 
months, and incomplete genotype data at 12 months would be excluded from the sample 
at all transition points.  Excluding these patients maintained a constant sample size over 
all time points.   
Method 3: Similarly to Method 2, this method also assessed the new development 
of resistance as opposed to prevalence of cumulative resistance.  Unlike the previous two 
methods, the sample size varies at each time point.  Patients not meeting any of the three 
criteria at any single time point were only excluded from the sample at that specific time 
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point.  The patient in the Method 2 example would still be included in the sample size at 
the first transition point between baseline and 6 months as not newly resistant.     
 
Adherence 
 Of note, collection of data on rates of optimal adherence at each time point began 
only after the baseline of the study, as it was not part of the initial study.  Thus, adherence 
data is incomplete at all time points.  Only a descriptive analysis of adherence and 
resistance was able to be completed.     





 Resistance data was available for 396 patients from YNHH (n=192) and HH 
(n=204).  Table 1 summarizes characteristics of the study population prior to study 
initiation.  The sample sizes in this table reflect the number of patients that answered the 
question on the survey.   
TABLE 1.  Characteristics of Study Population.A   
                                                                   YNHH                           HH               TOTAL  
DEMOGRAPHICS
Mean Age ( N=390) -- 43.7 43.2 43.4 
Gender (N=395) Male 
Female 
101 (53%) 
































































                                                 
A Data is valid at time of study initiation.  N = number of patients for whom data is complete.   
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Duration of HAART 
(N=187) 








Duration of HIV infection 
(N=394) 
≤ 2 years 
3-10 years      




























 Differences in population characteristics between the HH and YNHH patients 
participating in the resistance substudy existed in the percentage of patients on HAART 
(60% at HH vs. 78% at YNHH (χ2 (1, N=386) = 13.131, p = .000)), length of therapy 
(70% at HH were on HAART for > 3 years vs. 57% at YNHH (χ2 (1, N=251) = 4.111, p = 
.042)), education (51% at HH had not graduated high school vs. 36% at YNHH (χ2 (1, 
N=251) = 9.162, p = .000)), percentage of patients on welfare (78% at HH vs. 62% at 
YNHH (χ2 (1, N=395) = 11.571, p = .001)), and racial composition (54% Hispanic and 
26% African-American at HH vs. 14% Hispanic and 51% African-American at YNHH 
(χ2 (3, N=389) = 68.661, p = .000)).   
 Table 2 provides a cross-sectional analysis of genotype at each time point, i.e. 
baseline, 6 months, 12 months, and 18 months for the entire sample.  Sample size varies 
across time points as samples were tested for resistance from discard plasma only if a 
viral load was tested for at the clinic visit and enough plasma remained for genotype 
testing.  Because no extra blood was drawn from patients, not every patient had a sample 
available for genotype testing at every time point.  The percentages of patients with ND 
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VL were 46.6% at baseline, 52.2% at 6 months, 54.4% at 12 months, and 56.7% at 18 
months.  The percentages of patients with WT genotype were 26% at baseline, 14.2% at 6 
months, 17.1% at 12 months, and 21% at 18 months.  Overall, 27.4% of patients had 
drug-resistant mutations at baseline, 33.6% had drug-resistant mutations at 6 months, 
28.5% of patients had drug-resistant mutations at 12 months, and 22.3% of patients had 
drug-resistant mutations at 18 months (this represents a cross-sectional prevalence of 
resistance – changes cumulative resistance based on historical genotype, the primary 
outcome of the study, will be presented in the next section).  Also see Table 2 for cross-
sectional prevalence of resistance by drug class.   
TABLE 2.  Cross-sectional Prevalence of Genotype in Study Population.   
Genotype Baseline 6 months 12 months 18 months 
ND VL 158 (46.6%) 129 (52.2%) 105 (54.4%) 89 (56.7%) 
WT  88 (26.0%) 35 (14.2%) 33 (17.1%) 33 (21.0%) 
Total Resistant 93 (27.4%) 83 (33.6%) 55 (28.5%)B 35 (22.3%)C 
1-classD 51 (55%) 21 (25%) 18 (33%) 21 (60%) 
2-class 33 (35%) 33 (40%) 23 (42%) 10 (29%) 
3-class 9 (10%) 5 (6%) 2 (4%) 3 (11%) 
Revertant 0 (0%) 24 (29%) 10 (18%) 0 (0%) 
Patients 339 247 193 157 
 
 
                                                 
B This total includes two samples with resistant mutations on partial resistance genotype assay.  Full 
genotype was not performed. 
C This total includes one sample with resistant mutations on partial resistance genotype assay.  Full 
genotype was not performed. 
D Percentages for drug-classes and revertants based on total resistants.   
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Changes in Resistance 
 As noted previously, patients were divided into three groups in order to measure 
changes in the prevalence of cumulative resistance.  Out of the total sample of 396 
patients, 84 patients had data available for all 18 months of the study (group 1), 153 
patients had data available for at least 12 consecutive months (group 2), and 204 patients 
had data available for at least the first six months from baseline (group 3).  Groups are 
cumulative such that all patients in the 18-month group are included in the 6-month and 
12-month groups, and all patients in the 12-month group are included in the 6-month 
group.  Characteristics of patients among these three groups did not greatly differ except 
for the percentage of patients on HAART therapy.  71% of patients from the 6-month 
group were on HAART therapy and 69% of patients from the 12-month group, while 
83% of patients from the 18-month group were on HAART therapy at the initiation of the 
study (χ2 (3, N=386) = 13.794, p = .003).  The method of transmission of virus was not 
different between groups (χ2 (9, N=387) = 1.816, p = .998).  Baseline VL did not 
significantly differ (F(3,338) = 2.546, ns).       
 Tables 3-5 present the cumulative resistance over time within each group of 
subjects.  As noted previously, sample size differs among the different groups.  The 
sample size within each group is also affected by samples with inadequate genomic 
material (see Discussion for explanation/limitations) for which only a partial resistance 
genotype assay was performed.  These samples were excluded from the analysis.  For 
example, the presence of resistance in a partial genotype assay showing only WT 
genotype would be unknown.  For the 18-month group, 6/84 patients had incomplete 
 26
genotype data at 12 months and 18 months.  The total sample size is 78 patients with 
complete data.  3 of these 6 patients at 12 and 18 months had previous drug-resistant 
mutations with no new resistance possible, giving a sample size for calculation of 
incidence of new resistance of 81 patients at 12 and 18 months.    For the 12-month 
group, 9/153 patients had incomplete genotype data at 12 months and 6 of these 9 
patients had previous drug-resistant mutations again allowing them to be classified as not 
newly resistant.   
Method 1.  The prevalence of resistance in the 18-month group (n=78) increased by 
14.1% over 18 months from 32.1% to 46.2% (54.2% to 58.3% at HH; 22% to 40.7% at 
YNHH).  Cumulative resistance in the 12-month group (n=144) increased by 18.8% over 
12 months from 31.9% to 50.7% (44.4% to 60.3% at HH; 22.2% to 43.2% at YNHH).  
Cumulative resistance in the 6-month group (n=204) increased by 12.2% from 30.9% to 
43.1% (47.2% to 55.1% at HH; 18.3% to 33.9% at YNHH).  Figures 2-4 illustrate these 
changes in cumulative resistance over time within each group of subjects.  The Mantel-
Haenszel chi-square statistics for linear trends are 1) for the 18-month group (χ2 (1, n=78) 
= 3.084, p = .079) 2) for the 12-month group (χ2 (1, n=144) = 10.328, p = .001.  Pearson 
chi-square was done for the 6-month group (χ2 (1, n=204) = 6.571, p = .010).    
Method 2.  The 6-month incidence of resistance in the 18-month group was 7.1% at 6 
months (n=84), 1.2% at 12 months (n=81), and 4.8% at 18 months (n=81) (3.4%, 3.6%, 
0% at HH; 9.1%, 0%, 7.4% at YNHH).  The 6-month incidence of new resistance in the 
12-month group was 12.4% at 6 months (n=153) and 5.3% at 12 months (n=150) (10.3%, 
4.6% at HH; 14.1%, 5.9% at YNHH).  The incidence of new resistance in 6-month group 
(n=204) was 12.3% at 6 months (7.9% at HH, 15.7% at YNHH).   
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Method 3.  The 6-month incidence of resistance in the 18-month group (n=81) was 7.4% 
at 6 months, 1.2% at 12 months, and 4.9% at 18 months (0%, 3.7%, 0% at HH; 11.1%, 
0%, 7.4% at YNHH).  The 6-month incidence of new resistance in the 12-month group 
(n=150) was 12.7% at 6 months and 5.3% at 12 months (10.8%, 4.6% at HH; 14.1%, 
5.9% at YNHH).  The incidence of new resistance in the 6-month group (n=204) was 
12.3% at 6 months (6.8% at HH; 14.8% at YNHH). 
TABLE 3.  Cumulative resistance and incidence of new resistance among patients 
with 18 months of genotype data (group 1). 
 
Genotype Baseline 6 months 12 months 18 months 
ND VL 44 (52.4%) 50 (59.5%) 50 (64.1%) 47 (60.3%) 
WT  15 (17.9%) 10 (11.9%) 9 (11.5%) 11 (14.1%) 
Total Resistant 25 (29.8%) 24 (28.6%) 19 (24.4%) 20 (25.6%) 
1-classE 13 (52%) 4 (17%) 6 (32%) 13 (65%) 
2-class 9 (36%) 16 (67%) 11 (58%) 6 (30%) 
3-class 3 (12%) 2 (8%) 1 (5%) 1 (5%) 
Revertant 0 (0%) 2 (8%) 1 (5%) 0 (0%) 
New Resistance (n=81) -- 6 (7.4%) 1 (1.2%) 4 (4.9%) 










                                                 
E Percentages for drug-classes and revertants based on total resistants.   
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FIGURE 2. Prevalence of ART resistance over time in patients with 18 consecutive 




















χ2 = 3.084, p = .079 
                                                 













TABLE 4.  Cumulative resistance and incidence of new resistance among patients 
with 12 consecutive months of genotype data (group 2).   
 
Genotype Baseline 6 months 12 months 
ND VL 74 (48.4%) 85 (55.6%) 84 (58.3%) 
WT  33 (21.6%) 16 (10.5%) 22 (15.3%) 
Total Resistant 46 (30.1%) 52 (34.0%) 38 (26.4%) 
1-classG 22 (48%) 12 (23%) 13 (34%) 
2-class 16 (35%) 22 (42%) 16 (42%) 
3-class 8 (17%) 5 (10%) 1 (3%) 
Revertant 0 (0%) 13 (25%) 6 (16%) 
New Resistance (n=150) -- 19 (12.7%) 8 (5.3%) 






                                                 
G Percentages for drug-classes and revertants based on total resistants. 
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FIGURE 3. Prevalence of ART resistance over time in patients with 12 consecutive 




















χ2 = 10.328, p = .001
                                                 







TABLE 5.  Cumulative resistance and incidence of new resistance among patients 
with genotype data at baseline and 6 months (group 3). 
 
Genotype Baseline 6 months 
ND VL 95 (46.6%) 110 (53.9%) 
WT  46 (22.5%) 24 (11.8%) 
Total Resistant 63 (30.9%) 70 (34.3%) 
1-classI 32 (51%) 17 (24%) 
2-class 23 (37%) 29 (41%) 
3-class 8 (12%) 5 (7%) 
Revertant 0 19 (28%) 
New Resistance (n=204) -- 25 (12.3%) 
Cumulative Resistance (n=204) 63 (30.9%) 88 (43.1%) 
 





                                                 
I Percentages for drug-classes and revertants based on total resistants. 
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FIGURE 4. Prevalence of ART resistance over time in patients with 6 consecutive 



















χ2 = 6.571, p = .010 
                                                 
J Pearson χ2 test computed for total sample.  
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      The 14.1% rate of increase in the 18-month group (mean = .78% per month) was 
lower than rates of increase in the 12-month group (mean = 1.56% per month) and in the 
6-month group (mean = 2.04% per month).  The difference in 6-month rates of increase 
between the three groups was significant (χ2 (2, N=204) = 7.405, p = .025).    
Overall, 37 patients developed new identifiable drug-resistant mutations during 
the time period of this study.  The only significant differences between this group with 
new resistance and the total sample were the gender and clinic location of the patients.  
8/37 patients with new resistance were male while 224/395 (refer to Table 1 for complete 
statistics) patients were male in the total sample (χ2 (1, N=395) = 20.472, p = .000).  
27/37 patients with new mutations were at YNHH while 10/37 patients were at YNHH 
(χ2 (1, N=396) = 9.908, p = .002).    
 
Adherence 
 Data on the number of patients who maintained optimal adherence (>95% 
adherence) was available for a small sample of patients at each time point.  The table 
below shows the number of patients optimally adherent at each time point.   
Table 6.  Number of patients with >95% adherence at each time point 
 Baseline 6 months 12 months  18 months 
>95% Adherence 55 (72%) 126 (82%) 142 (82%) 122 (82%) 
TotalK  76 154 174 149 
.   
 
                                                 
K Total indicates number of patients for whom this data is available.   
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 A description of the adherence data is provided here due to the smaller sample 
size for this data.  Adherence rates in each group are shown in Table 7.   
Table 7. Percentage of patients with >95% adherence rates by group. 
 Baseline 6 months 12 months 18 months 
6-month group  73% (N=48)L 86% (N=106) -- -- 
12-month group  63% (N=30) 89% (N=74) 80% (N=104) -- 
18-month group 69% (N=13) 88% (N=42) 77% (N=61) 84% (N=61)
 
 Adherence rates among the patients with new development of resistance who had 
adherence data available during the course of the study were 86% in the first 6 months, 
80% in the second 6 months, 80% in the third 6 months, and 63% in the last 6 months.  
Of patients in the 6-month group who maintained optimal adherence during the first 6 
months, 2/18 developed new resistance.  Of patients in the 12-month group who 
maintained optimal adherence in the first 6 months, 2/10 developed new resistance, and 
2/49 patients who maintained optimal adherence in the second 6 months developed new 
resistance.  No patients who maintained optimal adherence for at least 6 consecutive 
months in the 18-month group developed new resistance during the maintenance periods.   
 
Genotype Transitions 
 Table 8 shows the patterns of changes in genotype for all 6-month transitions in 
the study.  Patients with more than six months of genotype data are thus represented more 
than once in the sample of all such transitions.  This data provides a more complete 
                                                 
L N = number of patients for whom data is available.  
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picture of the complexities of the development of non-detectability, WT genotype, and 
resistance in a clinic scenario.   










WT 2.5% ND 
R 10.2% 
ND 25.3% 
WT 53.2% WT 
R 21.5% 
ND 28.6% 




 The results of an analysis of changes in the prevalence of resistance (using 
Method 1 from above) both 1) excluding all samples with revertant genotypes and 2) 





                                                 
M ND = nondetectable; WT = wild-type; R = drug-resistant 
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Table 9. Cumulative resistance (using Method 1) for all three groups excluding 
revertants from analysis. 
 
Group Baseline 6 months 12 months 18 months
6-month (n=185) 63 (34.1%) 77 (41.6%) -- -- 
12-month (n=127) 46 (36.2%) 56 (44.1%) 72 (56.7%) -- 
18-month (n=75) 25 (33.3%) 31 (41.3%) 31 (41.3%) 36 (48.0%)
 
Table 10. Cumulative resistance (using Method 1) for all three groups assuming 
revertant genotypes are not resistant. 
 
Group Baseline 6 months 12 months 18 months
6-month (n=204) 63 (30.8%) 77 (37.8%) -- -- 
12-month (n=144) 46 (31.9%) 56 (38.9%) 72 (50.0%) -- 
18-month (n=78) 25 (32.1%) 31 (39.7%) 31 (39.7%) 36 (46.1%)
 
 
Overall, rates of increase in cumulative resistance were similar with and without 
inclusion of revertants for the 6-month group (χ2 (1, N=204) = 2.799, p =. 064) and 12-
month group (χ2 (1, N=144) = .023, p =. 879), and rates of increase were identical for the 
18-month group.  The chi-square tests for significance were as follows: 1) 18-month 
group (χ2 (1, n=78) = 3.142, p = .076) 2) 12-month group (χ2 (1, n=78) = 9.736, p = .002) 
3) 6-month group (χ2 (1, n=78) = 2.131, p = .144).   
Regarding transitions involving revertant genotypes, of 34 total samples with 
revertant genotypes, 14 samples had genotype status available for the subsequent time 
point, and 25 samples had genotype status available for the preceding time point.  Of the 
14 revertant samples with subsequent time point genotype available, 5 transitioned to 
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ND, 6 transitioned to WT genotype, 1 transitioned to resistant genotype, and 2 remained 
revertant.  Of the 25 revertant samples with preceding time point genotype available, 3 
transitioned to revertant status from ND, 9 transitioned from WT genotype, 11 
transitioned from resistant genotype, and 2 transitioned from revertant genotype.  Of 
note, because patients went on and off ART throughout the study (and especially between 
6-month genotyping time points) due to variation in adherence, patient choice, and 
clinician-driven treatment interruptions, a minority of these transitions involve transitions 
to or from WT genotype.    
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DISCUSSION 
In this study, we analyzed patterns of ART resistance in a sample of HIV+ 
patients from the two largest HIV clinics in Connecticut and examined changes in 
prevalence of resistance utilizing longitudinal genotype testing.  This study provides an 
insight into the dynamics of how antiretroviral resistance changes over time in a 
population of HIV+ patients under a typical clinical care setting. We found a 14.1% 
increase in resistance among patients with 18 months of genotype data, an 18.8% 
increase among patients with 12 months of genotype data, and a 12.2% increase among 
patients with 6 months of genotype data.  These findings demonstrate that the burden of 
resistance in clinical populations is great and a major issue in the care of patients (from 
the time period of 2000-2003).      
The hypothesis in this study was that the cumulative prevalence of ART 
resistance in this patient population would increase at a rate of >5% per 6-month interval 
and the cumulative rate of increase during the 18-month period of data in this study will 
exceed 15%.  Prevalence of resistance increased in patients who had genotype data 
available for 6 months, 12 months, and 18 months.  The 14.1% increase in cumulative 
resistance in the 18-month population did not meet the hypothesized 15% increase in 
prevalence over 18 months.  As few studies have examined historical genotypes, the 
hypothesis set at the beginning of this study was only an estimate.  The results in this 
study approached the hypothesized 15% increase and have equally important 
consequences.  Also, the 6-month increase in cumulative resistance was greater than 5% 
in the 6-month group, both 6-month periods in the 12-month group, and the first and last 
6-month period of the 18-month group.  Observing the incidence of new resistance, this 
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was greater than 5% in all 6-month periods except for the second and third 6-month 
period of the 18-month group.   
The 18-month group had the lowest rate of increase in the cumulative resistance.  
It is possible that patients who made all four clinic visits over 18 months (and thus were 
more likely to come to clinic and keep appointments) led more stable lives with less 
active drug use and were seen more frequently by their clinician, which may have 
provided more opportunity to change therapy sooner before resistance emerged.  These 
data were not captured in the present study.  Appointment nonadherence has been 
associated with failure to suppress viral load at two or more time points and with AIDS-
defining CD4 counts (36, 37), although Purkayastha et al. did not find an association 
between clinic appointments and ND VL (38).  The 18-month group may have had higher 
rates of viral suppression during the study period.  Several studies have also associated 
lower rates of adherence with missed clinical appointments (39, 40).  The available data 
does not show greater rates of adherence to drug therapy in this 18-month group.  
However, this was difficult to assess statistically in the present study due to incomplete 
data on adherence.  As discussed in the introduction, a higher level of adherence (>95%) 
to antiretroviral therapy with viral suppression is linked to lower levels of development of 
drug resistance.  Sub-optimal adherence to certain classes of drugs may lead to higher 
levels of resistance (16, 17).  More data on average rates of adherence would be useful to 
characterize these relationships within the groups in this study.  IDU and high baseline 
plasma VL are also associated with development of resistance.  The groups did not differ 
significantly in IDU use as a risk factor for original HIV infection or in mean plasma VL.   
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Cumulative resistance increased at both clinical sites in the study.   The rate of 
development of new resistance at YNHH was greater than at HH.  Since HH had a higher 
initial prevalence, the population may have been closer to the “plateau” of resistance.  At 
54%, the baseline resistance at HH was 2.5 times the baseline resistance at YNHH of 
22%.  At such high levels of baseline resistance, it is possible that this plateau of 
resistance was reached in this inner city community clinic, which could account for the 
lower rate of new resistance development at HH.  As very high levels of adherence are 
associated with a decreased likelihood of developing drug resistance, a plateau effect may 
be possible if a core subset of the population maintains excellent adherence.  Further, a 
portion of the remaining non-resistant patients may not be on drug therapy and thus have 
no selective pressure for resistance. One could hypothesize that the rate of resistance in 
any population would reach a plateau once the major at-risk populations have developed 
resistance (e.g. poor adherers and patients on insufficiently potent regimens). Alternately, 
the difference in baseline levels of resistance and development of new resistance may 
reflect differences in provider skills, prescribing habits, demographics, and adherence.  
The HH clinic population had more Hispanic patients, lower levels of education, and a 
higher percentage of patients on welfare.  A longer period of genotypic testing is needed 
to determine whether a plateau effect exists and predictors of such an effect.  Other clinic 
populations should be studied as well. Of note, as discussed earlier, the population of 
chronically-infected HIV patients studied by Richman et al. between 1996 and 1999 
showed 48% resistance.  This is similar to the resistance rates at HH documented for the 
period immediately following from 2000-2003.  The HH clinic population may represent 
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a similar group to this early HAART era population.  It is possible that a prevalence of 
50% represents a resistance level approaching a plateau. 
Prior studies did not genotype all available samples at all time points and thus 
may have missed some resistance.  This study represents a more in-depth look at trends in 
resistance than the Harrigan et al. study (23), which originally advocated the longitudinal 
testing approach based on historical genotype as opposed to the cross-sectional 
genotyping method for following changes in resistance.  That study represented ~29% of 
treated HIV-1 infected individuals in British Columbia.  In the Harrigan et al. study, 
genotype testing was performed at the discretion of the clinician and was not done for all 
samples with detectable VL as in the present study.  The frequency of genotyping was a 
median of five tests over a median of 34 months.  The frequency of genotype testing in 
our study was four tests over an 18 month period.  While our study looked at all patients 
under clinical care participating in the resistance substudy, the Harrigan et al. study was 
biased towards patients in whom therapy was failing and for whom clinicians saw value 
in performing multiple tests for drug resistance. 
By identifying specific mutations, genotypic assays have become a common 
method in the detection of drug resistance.  However, there are a few limitations that 
arise from this method.  As with any laboratory testing methods, there is the potential for 
laboratory error in the methods as well as reporting of results.  Of note, genotype assays 
may not be able to detect mixtures of wild-type and resistant viral populations, as current 
assays can only detect viruses representing greater than 5 to 20 percent of the plasma 
viral population (12).  Due to the possibility of latent strains of resistant virus, resistance 
may go undetected in certain individuals at certain time points as they test only virus 
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circulating in plasma.  As the present study performed genotypes on longitudinally 
obtained samples thus obtaining both historical and current genotypes to characterize the 
prevalence of resistance, this limitation was offset to some degree. To fully correct this 
limitation, sampling of the archived virus from latently infected T-cells and sampling of 
sanctuary sites such as the genital-urinary compartment and central nervous system 
would need to be performed.   
The genotype testing in our study was limited to available samples from discard 
plasma originally tested for VL.  Complete genotyping was not possible on a few samples 
because 1) a genotype was attempted on all samples irrespective of viral load (most 
clinical labs will not test a sample for resistance if the viral load is < 1000 copies as the 
yield is low and genetic material is insufficient for sequencing 2) no additional blood was 
drawn other than that for routine clinical care; this discard plasma was freezed-thawed at 
least twice, which can lead to decreased viral RNA copies.     
Patients in this study represent a diverse population of patients with regards to 
HIV risk factors, socioeconomic and racial background, and sexual orientation.  Of 
patients with such data available, 68% were already on HAART therapy prior to baseline, 
52% had been on HAART therapy for greater than three years, and 88% had been 
infected with HIV for greater than two years.  While this clinical setting provides a 
realistic look at development of resistance for clinicians, certain limitations arise in this 
study.  The time course of HIV infection and HAART therapy factoring into baseline 
genotype is unique for each patient.  The presence of back-revertants in a minority of 
patients likely reflects the fact that patients frequently went on and off ART, as is real-life 
clinical situations.  In the main analysis, revertant genotypes were counted as drug-
 43
resistant.  From the analysis of changes in cumulative resistance both excluding 
revertants and assuming revertants are not resistant, because patients’ genotypes prior to 
baseline are unknown, overall prevalence of resistance is likely underestimated.  ND VL 
at baseline does not necessarily indicate absence of resistance prior to baseline.  Thus, 
while this study indeed relies on historical genotype to calculate cumulative resistance, 
the baseline level of resistance represents a cross-sectional resistance at the arbitrary 
point in time of enrollment in the study.  Furthermore, enrollment in the Options Project 
was staggered over two years.  The data on cross-sectional resistance presented in Table 
2 provides information relative to each patient’s baseline, and cannot be interpreted as a 
trend beginning in a specific year.   
Further studies are needed to examine the possibility of a resistance plateau as 
discussed earlier.  Also, while this study only examined development of first-time 
resistance in clinic populations, a further analysis of patterns of the accumulation of 
additional drug-resistant mutations would be useful in the clinical setting.   
 
Antiretroviral resistance will remain as a major challenge as increasing numbers 
of HIV+ patients are placed on treatment and transmission of drug-resistant virus 
continues in the community.  The prevalence of antiretroviral resistance in all groups of 
HIV+ patients has been increasing over the past decade with the advent of multi-drug 
HAART regimens.  This study is among the first to look at these patterns of antiretroviral 
resistance in a typical HIV+ patient population under clinical care.  Prevalence of 
resistance in this community has risen dramatically.  The findings of this study 
demonstrate the importance of monitoring for HIV drug resistance trends in patients in 
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clinical care (as is done routinely for other infectious pathogens, e.g. hospital and 
community acquired infections). Further, these data can help in the design of future 
studies on how best to address resistance in a clinical setting through physician education, 
treatment regimen adjustments, reduction of transmission risks, and utilization of 
genotype testing.    
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